Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)

Harmony Biosciences Holdings, Inc.

2025-Q3 EPS reported $2.32 revenue$624,677,000

Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.
Average patient count rose by ~500 to 8,100 in Q3, the largest quarterly increase ever.
2025 revenue guidance raised to $845-$865M from prior $820-$860M.
Full Q3 2025 earnings and conference call scheduled for November 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.